HRP20211466T1 - Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka - Google Patents
Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka Download PDFInfo
- Publication number
- HRP20211466T1 HRP20211466T1 HRP20211466TT HRP20211466T HRP20211466T1 HR P20211466 T1 HRP20211466 T1 HR P20211466T1 HR P20211466T T HRP20211466T T HR P20211466TT HR P20211466 T HRP20211466 T HR P20211466T HR P20211466 T1 HRP20211466 T1 HR P20211466T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- alkylene
- cancer
- image
- solvate
- Prior art date
Links
- 229940045985 antineoplastic platinum compound Drugs 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 150000003058 platinum compounds Chemical class 0.000 title 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 67
- 125000002947 alkylene group Chemical group 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 29
- 239000012453 solvate Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 18
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 7
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010023774 Large cell lung cancer Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 208000026037 malignant tumor of neck Diseases 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 229940125565 BMS-986016 Drugs 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 206010071980 BRCA1 gene mutation Diseases 0.000 claims 1
- 206010071981 BRCA2 gene mutation Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 238000002619 cancer immunotherapy Methods 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000025036 lymphosarcoma Diseases 0.000 claims 1
- 208000006178 malignant mesothelioma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 229950010773 pidilizumab Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229940126625 tavolimab Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15198739 | 2015-12-09 | ||
| PCT/EP2016/080453 WO2017097986A1 (en) | 2015-12-09 | 2016-12-09 | Monomaleimide-functionalized platinum compounds for cancer therapy |
| EP16822917.7A EP3386997B1 (en) | 2015-12-09 | 2016-12-09 | Monomaleimide-functionalized platinum compounds for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211466T1 true HRP20211466T1 (hr) | 2021-12-24 |
Family
ID=54849106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211466TT HRP20211466T1 (hr) | 2015-12-09 | 2016-12-09 | Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10723748B2 (OSRAM) |
| EP (1) | EP3386997B1 (OSRAM) |
| JP (1) | JP6867652B2 (OSRAM) |
| CN (1) | CN108368143B (OSRAM) |
| AU (1) | AU2016367306B2 (OSRAM) |
| CA (1) | CA3004630A1 (OSRAM) |
| CY (1) | CY1124529T1 (OSRAM) |
| DK (1) | DK3386997T3 (OSRAM) |
| ES (1) | ES2898704T3 (OSRAM) |
| HR (1) | HRP20211466T1 (OSRAM) |
| HU (1) | HUE056897T2 (OSRAM) |
| IL (1) | IL259864B (OSRAM) |
| LT (1) | LT3386997T (OSRAM) |
| MX (1) | MX377528B (OSRAM) |
| PL (1) | PL3386997T3 (OSRAM) |
| PT (1) | PT3386997T (OSRAM) |
| RS (1) | RS62412B1 (OSRAM) |
| SG (1) | SG11201804885TA (OSRAM) |
| SI (1) | SI3386997T1 (OSRAM) |
| SM (1) | SMT202100709T1 (OSRAM) |
| WO (1) | WO2017097986A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200250A1 (en) * | 2014-06-23 | 2015-12-30 | Blend Therapeutics, Inc. | Platinum compounds, compositions, and uses thereof |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CN109171001A (zh) * | 2018-09-14 | 2019-01-11 | 上海烟草集团有限责任公司 | 草酸钠在降低卷烟烟气中TSNAs释放量中的应用 |
| EP4085053A4 (en) * | 2019-12-31 | 2023-12-27 | Kinnate Biopharma Inc. | TREATING CANCER WITH CDK12/13 INHIBITORS |
| CN114163479B (zh) * | 2020-09-11 | 2025-05-16 | 上海海聚生物科技有限公司 | 一类治疗癌症用的铂类化合物及其制备方法 |
| US20230339997A1 (en) * | 2020-09-11 | 2023-10-26 | Shanghai Haiju Biological Technology Co., Ltd. | Class of platinum compounds for treating cancer, and method for preparation thereof |
| CN114539320A (zh) * | 2020-11-25 | 2022-05-27 | 北京大学 | 辐射激活的四价铂配合物及其用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CH605550A5 (OSRAM) | 1972-06-08 | 1978-09-29 | Research Corp | |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| ATE12348T1 (de) | 1980-11-10 | 1985-04-15 | Gersonde Klaus Prof Dr | Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens. |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS607934A (ja) | 1983-06-29 | 1985-01-16 | Dai Ichi Seiyaku Co Ltd | リポソ−ムの製造方法 |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3486459D1 (de) | 1983-09-26 | 1997-12-11 | Udo Dr Med Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| CS269719B1 (en) | 1986-12-29 | 1990-05-14 | Kiss Frantisek | Platinum cytostatic |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| KR100575070B1 (ko) | 1997-09-29 | 2006-05-03 | 넥타르 테라퓨틱스 | 안정화된 생활성 제제 및 이의 사용 방법 |
| JP4169478B2 (ja) | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| DE19926154A1 (de) | 1999-06-09 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung |
| AUPQ641100A0 (en) | 2000-03-23 | 2000-04-15 | Australia Nuclear Science & Technology Organisation | Methods of synthesis and use of radiolabelled platinum chemotherapeutic ag ents |
| PT1280520E (pt) | 2000-05-10 | 2014-12-16 | Novartis Ag | Pós à base de fosfolípidos para administração de fármacos |
| ES2364636T3 (es) | 2001-12-19 | 2011-09-08 | Novartis Ag | Administración pulmonar de aminoglucósidos. |
| DE10314780A1 (de) | 2003-03-19 | 2004-09-30 | Ktb Tumorforschungsgesellschaft Mbh | Proteinbindende Derivate von Platinkomplexen mit Cyclobutan-1,1-dicarboxylatliganden |
| EP1608358A1 (en) | 2003-03-31 | 2005-12-28 | Pliva-Lachema A.S. | Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof |
| CZ296169B6 (cs) | 2004-09-08 | 2006-01-11 | Pliva - Lachema A. S. | Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| CZ296459B6 (cs) | 2004-09-14 | 2006-03-15 | Pliva-Lachema A. S. | Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo |
| US20060205810A1 (en) | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
| CZ300590B6 (cs) | 2006-06-20 | 2009-06-24 | Pliva - Lachema A. S. | Farmaceutická kompozice pro injekcní podání |
| CZ300424B6 (cs) | 2006-06-20 | 2009-05-13 | Pliva - Lachema A. S. | Farmaceutická kompozice pro perorální podání |
| CZ300120B6 (cs) | 2006-06-20 | 2009-02-11 | Pliva - Lachema A. S. | Farmaceutická kompozice pro injekcní podání |
| WO2013085925A1 (en) | 2011-12-05 | 2013-06-13 | Igenica, Inc. | Antibody-drug conjugates and related compounds, compositions, and methods |
| MX366864B (es) * | 2012-02-27 | 2019-07-26 | Amunix Operating Inc | Composiciones de conjugados de xten y métodos para realizarlas. |
| WO2015052516A1 (en) * | 2013-10-08 | 2015-04-16 | Atlas Genetics Limited | Labelling compounds and their use in assays |
| WO2015102922A1 (en) * | 2013-12-31 | 2015-07-09 | Blend Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of cancers |
| WO2015200250A1 (en) * | 2014-06-23 | 2015-12-30 | Blend Therapeutics, Inc. | Platinum compounds, compositions, and uses thereof |
| EP3313393A4 (en) | 2015-06-23 | 2019-01-09 | Placon Therapeutics, Inc. | PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF |
| WO2016209918A1 (en) | 2015-06-23 | 2016-12-29 | Placon Therapeutics, Inc. | Platinum compounds, compositions, and uses thereof |
| EP3313527B1 (en) | 2015-06-29 | 2021-02-24 | Case Western Reserve University | Anticancer drug-containing plant virus particles |
| CN108449940B (zh) | 2015-07-12 | 2021-06-08 | 杭州多禧生物科技有限公司 | 与细胞结合分子的共轭偶联的桥连接体 |
| EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
| EP3482205A1 (en) | 2016-07-08 | 2019-05-15 | H. Hoffnabb-La Roche Ag | Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment |
| WO2018026742A1 (en) | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
| CN108164512B (zh) | 2017-12-27 | 2021-05-25 | 沈阳药科大学 | 一类具有生物粘附作用的马来酰亚胺型前药及其在口服药物传递中的应用 |
| CN108187063B (zh) | 2018-01-09 | 2020-09-08 | 沈阳药科大学 | 白蛋白结合型抗肿瘤药-马来酰亚胺分子前药 |
-
2016
- 2016-12-09 HU HUE16822917A patent/HUE056897T2/hu unknown
- 2016-12-09 DK DK16822917.7T patent/DK3386997T3/da active
- 2016-12-09 SM SM20210709T patent/SMT202100709T1/it unknown
- 2016-12-09 WO PCT/EP2016/080453 patent/WO2017097986A1/en not_active Ceased
- 2016-12-09 SG SG11201804885TA patent/SG11201804885TA/en unknown
- 2016-12-09 US US16/060,559 patent/US10723748B2/en active Active
- 2016-12-09 PL PL16822917T patent/PL3386997T3/pl unknown
- 2016-12-09 EP EP16822917.7A patent/EP3386997B1/en active Active
- 2016-12-09 AU AU2016367306A patent/AU2016367306B2/en not_active Ceased
- 2016-12-09 HR HRP20211466TT patent/HRP20211466T1/hr unknown
- 2016-12-09 CN CN201680072428.4A patent/CN108368143B/zh not_active Expired - Fee Related
- 2016-12-09 RS RS20211187A patent/RS62412B1/sr unknown
- 2016-12-09 MX MX2018006953A patent/MX377528B/es active IP Right Grant
- 2016-12-09 PT PT16822917T patent/PT3386997T/pt unknown
- 2016-12-09 JP JP2018529981A patent/JP6867652B2/ja active Active
- 2016-12-09 CA CA3004630A patent/CA3004630A1/en active Pending
- 2016-12-09 IL IL259864A patent/IL259864B/en unknown
- 2016-12-09 LT LTEPPCT/EP2016/080453T patent/LT3386997T/lt unknown
- 2016-12-09 ES ES16822917T patent/ES2898704T3/es active Active
- 2016-12-09 SI SI201631342T patent/SI3386997T1/sl unknown
-
2020
- 2020-06-17 US US16/904,528 patent/US11572379B2/en active Active
-
2021
- 2021-09-27 CY CY20211100840T patent/CY1124529T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL259864A (en) | 2018-07-31 |
| LT3386997T (lt) | 2021-12-10 |
| CN108368143A (zh) | 2018-08-03 |
| DK3386997T3 (da) | 2021-09-20 |
| SI3386997T1 (sl) | 2021-11-30 |
| SMT202100709T1 (it) | 2022-01-10 |
| AU2016367306A1 (en) | 2018-06-14 |
| HUE056897T2 (hu) | 2022-03-28 |
| JP6867652B2 (ja) | 2021-05-12 |
| CN108368143B (zh) | 2022-02-01 |
| MX377528B (es) | 2025-03-10 |
| MX2018006953A (es) | 2019-05-16 |
| EP3386997A1 (en) | 2018-10-17 |
| PL3386997T3 (pl) | 2021-12-13 |
| US20210002313A1 (en) | 2021-01-07 |
| US11572379B2 (en) | 2023-02-07 |
| EP3386997B1 (en) | 2021-06-30 |
| ES2898704T3 (es) | 2022-03-08 |
| PT3386997T (pt) | 2021-11-04 |
| US20180354979A1 (en) | 2018-12-13 |
| CY1124529T1 (el) | 2022-07-22 |
| WO2017097986A1 (en) | 2017-06-15 |
| CA3004630A1 (en) | 2017-06-15 |
| AU2016367306B2 (en) | 2021-04-22 |
| US10723748B2 (en) | 2020-07-28 |
| SG11201804885TA (en) | 2018-07-30 |
| JP2018538292A (ja) | 2018-12-27 |
| RS62412B1 (sr) | 2021-10-29 |
| IL259864B (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211466T1 (hr) | Spojevi platine funkcionalizirani monomaleimidom, namijenjeni terapiji raka | |
| JP2017533266A5 (OSRAM) | ||
| AU2018360853B2 (en) | Modulators of the integrated stress pathway | |
| TWI872824B (zh) | 抗ｈｅｒ３抗體-藥物結合物之製造方法 | |
| HRP20171534T1 (hr) | Derivati fosfora kao inhibitori kinaza | |
| AU2020281003A1 (en) | Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts | |
| CA3009474A1 (en) | Heterocyclic compounds as immunomodulators | |
| ME02887B (me) | 2-(2,4,5-supstituisani-anilino) pirimidinski derivati kao egfr modulatori korisni za tretman raka | |
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| KR20190015492A (ko) | 화학적 화합물 | |
| JP2018538292A5 (OSRAM) | ||
| WO2018031680A1 (en) | Novel compounds, uses and methods for their preparation | |
| HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
| WO2019193540A1 (en) | Heteroaryl derivatives of formula (i) as atf4 inhibitors | |
| AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
| ME02627B (me) | 6-alkinil piridini kao smac mimetici | |
| AR085398A1 (es) | Ureas asimetricas y usos medicos de las mismas | |
| HRP20211923T1 (hr) | Pirimidin-2-ilamino-1h-pirazoli kao inhibitori lrrk2 za uporabu u liječenju neurodegenerativnih poremećaja | |
| HRP20192073T1 (hr) | Novi derivati amonija, postupak za njihovu pripravu te farmaceutski pripravci koji ih sadrže | |
| HRP20191704T1 (hr) | Multispecifična protutijela | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| WO2020012339A1 (en) | Chemical compounds | |
| JP2015504076A5 (OSRAM) | ||
| JPWO2021188769A5 (OSRAM) | ||
| AU2015316010B2 (en) | Crystalline forms of 6-( (6, 7-dimethoxyquinazolin-4-yl) oxy) -N,2-dimethylbenzofuran-3-carboxamide |